Quarterly ResultAug 5, 2026, 04:20 PM
Revolution Medicines Q2 Net Loss $(644.4)M; Raises $1.65B in Offering
AI Summary
Revolution Medicines reported a significant increase in net loss for the second quarter of 2026, reaching $(644.4) million, up from $(247.8) million in the prior year. The diluted net loss per share was $(3.06). Despite the growing losses, the company substantially strengthened its liquidity position through a public offering that generated $1.65 billion in net proceeds and the issuance of convertible senior notes for $487.1 million. As a result, cash, cash equivalents, and marketable securities collectively surged to $3.94 billion by June 30, 2026.
Key Highlights
- Net loss for the three months ended June 30, 2026, was $(644.4) million, up from $(247.8) million in 2025.
- Diluted net loss per share was $(3.06) for Q2 2026, compared to $(1.31) in Q2 2025.
- Total net loss for the six months ended June 30, 2026, reached $(1.098) billion.
- Cash and cash equivalents increased to $815.4 million as of June 30, 2026, from $383.7 million at year-end 2025.
- Marketable securities grew to $3.12 billion as of June 30, 2026, from $1.64 billion at year-end 2025.
- Net proceeds from a follow-on public offering in April 2026 totaled $1.65 billion.
- Net proceeds from the issuance of convertible senior notes were $487.1 million.
- Research and development expenses increased to $394.9 million in Q2 2026 from $224.1 million in Q2 2025.
Price Impact
More from RVMD